PHD

VANCOUVER, British Columbia, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional as well as…

New hires in Bioanalytical Sciences, Biostatistics, Clinical Regulatory, and Clinical Project Management will join the team of Drs. Srinivasan, Recknor, Ray, and Kelly to lead all clinical trials with new CROs VANCOUVER, Washington,…

The Central government has decided to put on hold the plan to make PhD the minimum qualification for recruitment of assistant professors this year, in view of the COVID-19 pandemic. The Ministry of…

What a gift ‘The Only Prayer You’ll Ever Need’ is! It challenges the reader to examine the words of prayer and use them as a framework to achieve our best life.…

Dr. Kortylewski is the Leading Authority on Bi-Functional Oligonucleotide Cancer Therapeutics and a Professor in the Department of Immuno-Oncology at the Beckman Research Institute at City of Hope National Medical Center  Dr.…

At Tokyo’s Yumenoshima Archery Ranges, it wasn’t just time that was testing Harvinder. During his matches, the weather also played tricks. It was raining on some occasions, and windy at other times.…

AUSTIN, Texas, 30 août 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ : XBIT) (« XBiotech ») a annoncé aujourd'hui l'arrivée de Mark Ziats, M.D. Ph.D., au poste de directeur médical. Le Dr Ziats participera au développement et à la…

AUSTIN, Texas, Aug. 30, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) („XBiotech“) hat heute die Aufnahme von Mark Ziats, M.D. Ph.D., als Medical Director bekanntgegeben. Dr. Ziats wird an der Entwicklung und Betreuung eines…

AUSTIN, Texas, Aug. 30, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) today announced the addition of Mark Ziats, M.D. Ph.D. as Medical Director. Dr. Ziats will be involved in developing and managing a diverse…

REDWOOD CITY, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Jim Wang, Ph.D.,…